Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:CRIS NASDAQ:MESO NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.51+2.8%$8.65$3.92▼$19.15$92.08M0.1184,153 shs45,296 shsCRISCuris$0.30+47.7%$0.50$0.18▼$2.48$8.02M3.05757,562 shs107.30 million shsMESOMesoblast$13.19-9.0%$14.89$10.32▼$21.50$1.88B2.05170,259 shs421,681 shsOCGNOcugen$1.50+9.5%$1.44$0.90▼$2.73$463.77M2.196.58 million shs57.01 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+2.84%+4.37%-0.28%+128.98%+31.05%CRISCuris+47.72%-29.79%-42.42%-45.27%-85.99%MESOMesoblast-9.03%-8.21%-10.03%-8.15%+25.02%OCGNOcugen+9.49%+20.97%+8.70%-19.79%+44.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.51+2.8%$8.65$3.92▼$19.15$92.08M0.1184,153 shs45,296 shsCRISCuris$0.30+47.7%$0.50$0.18▼$2.48$8.02M3.05757,562 shs107.30 million shsMESOMesoblast$13.19-9.0%$14.89$10.32▼$21.50$1.88B2.05170,259 shs421,681 shsOCGNOcugen$1.50+9.5%$1.44$0.90▼$2.73$463.77M2.196.58 million shs57.01 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+2.84%+4.37%-0.28%+128.98%+31.05%CRISCuris+47.72%-29.79%-42.42%-45.27%-85.99%MESOMesoblast-9.03%-8.21%-10.03%-8.15%+25.02%OCGNOcugen+9.49%+20.97%+8.70%-19.79%+44.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.50-9.61% DownsideCRISCuris 1.67Reduce$17.005,492.11% UpsideMESOMesoblast 2.33HoldN/AN/AOCGNOcugen 2.60Moderate Buy$9.50533.33% UpsideCurrent Analyst Ratings BreakdownLatest OCGN, ATRA, MESO, and CRIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/22/2026CRISCuris Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$13.004/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRISCuris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.78$5.00 per share2.10($5.34) per share-1.97CRISCuris$9.44M1.26N/AN/A$0.42 per share0.72MESOMesoblast$17.20M99.28N/AN/A$4.67 per share2.82OCGNOcugen$4.41M115.14N/AN/A($0.04) per share-37.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M-$0.67N/A7.51N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)CRISCuris-$7.58M-$1.19N/AN/AN/A-80.29%N/A-181.57%8/4/2026 (Estimated)MESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)Latest OCGN, ATRA, MESO, and CRIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million5/12/2026Q1 2026CRISCuris-$0.3267-$1.25-$0.9233-$1.25$1.69 millionN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A2.162.16CRISCurisN/A1.111.11MESOMesoblast0.101.581.41OCGNOcugen4.171.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CRISCuris29.97%MESOMesoblast1.43%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%CRISCuris5.78%MESOMesoblast18.80%OCGNOcugen3.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataCRISCuris6038.98 million36.73 millionNo DataMESOMesoblast80129.46 million105.12 millionOptionableOCGNOcugen80338.52 million325.15 millionOptionableOCGN, ATRA, MESO, and CRIS HeadlinesRecent News About These CompaniesOcugen: Financing Risk Is Lower, But The Clinical Bet Still Has To WorkJune 25 at 9:16 AM | seekingalpha.comOcugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from BrokeragesJune 25 at 4:15 AM | americanbankingnews.comOcugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst ViewJune 24 at 11:57 PM | finance.yahoo.comOcugen Inc. stock rises Tuesday, outperforms marketJune 24 at 8:55 AM | marketwatch.comOcugen (NASDAQ:OCGN) CFO Treerita Essali Johnson-Greene Acquires 21,000 SharesJune 18, 2026 | insidertrades.comHow The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst GuidanceJune 5, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | zacks.comOcugen Consolidates Financial Leadership Under New Accounting OfficerJune 3, 2026 | tipranks.comOcugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareJune 3, 2026 | zacks.comIs OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?June 3, 2026 | zacks.comOCGN's Catalyst Calendar for Trial Data and Filings Through 2028June 3, 2026 | zacks.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | finance.yahoo.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | globenewswire.comOcugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exitMay 26, 2026 | msn.comOcugen Announces Interim Chief Medical Officer Appointment TransitionMay 14, 2026 | tipranks.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | finance.yahoo.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | globenewswire.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCGN, ATRA, MESO, and CRIS Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$10.51 +0.29 (+2.84%) As of 06/26/2026 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Curis NASDAQ:CRIS$0.30 +0.10 (+47.72%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$0.30 -0.01 (-2.30%) As of 06/26/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Mesoblast NASDAQ:MESO$13.19 -1.31 (-9.03%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$13.28 +0.10 (+0.72%) As of 06/26/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Ocugen NASDAQ:OCGN$1.50 +0.13 (+9.49%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
